Vaccination against the coronavirus has started and campaigns are well advanced at the level of many countries. It is that the need is urgent and the drug companies and other laboratories are in great demand. But while the campaigns are well underway, and given public concern, it becomes important for scientists to ensure the total, if not very acceptable, safety of the vaccines being administered. With this in mind, scientists based on a national prospective COVID-19 surveillance cohort in Scotland have highlighted a link between the AstraZeneca vaccine and ‘rare’ bleeding disorders.
Cases of Immune Thrombocytopenia (IPT) …
Researchers and experts at the University of Edinburgh discovered the link after analyzing data from 5.4 million people in Scotland between December 8 and April 14. At this point, 1.7 million had received their first dose of the Oxford vaccine while 800,000 had the Pfizer BioNTech vaccine.
According to the UK press who passed the information, the study found a slightly increased risk of an autoimmune bleeding disorder known as immune thrombocytopenia (ITP) in people who received a first dose of AZ (AstraZeneca vaccine).
The study, published Wednesday in the journal Nature Medicine, also suggests that there may be evidence of an increased risk of other bleeding and vascular events associated with the vaccine. However, these “risks are rare and comparable to those of other vaccines against diseases such as hepatitis B, measles, mumps, rubella and influenza,” according to the researchers.
Most importantly, there was further research into whether it was really the AstraZeneca vaccine that caused the blood clots and for what reasons. In each case, the scientists recalled that “the risk of developing a serious adverse event related to the vaccine is much lower than the risk of serious illness or death from the coronavirus, especially for the elderly and other vulnerable populations” .